Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers

Front Immunol. 2022 Dec 20:13:1082984. doi: 10.3389/fimmu.2022.1082984. eCollection 2022.

Qiang Feng^{1

2}, Baozhen Sun¹, Tianyi Xue^{2

3}, Rong Li², Chao Lin⁴, Yongjian Gao⁵, Liqun Sun⁶, Yue Zhuo³, Dongxu Wang²

¹ Department of Hepatobiliary and Pancreas Surgery, China - Japan Union Hospital of Jilin University, Changchun, China.
² Laboratory Animal Center, College of Animal Science, Jilin University, Changchun, China.
³ School of Acupuncture-Moxi bustion and Tuina, Changchun University of Chinese Medicine, Changchun, China.
⁴ School of Grain Science and Technology, Jilin Business and Technology College, Changchun, China.
⁵ Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
⁶ Department of Pathogenobiology, Jilin University Mycology Research Center, College of Basic Medical Sciences, Jilin University, Changchun, China.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.1025608.].

Keywords: CAR T cells; chimeric antigen receptors; digestive tumors; immunotherapy; xenograft models.